AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 60 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,940 | +65.2% | 8,746 | +6.3% | 0.00% | – |
| Q1 2023 | $2,385 | +108.3% | 8,224 | +223.4% | 0.00% | – |
| Q4 2022 | $1,145 | +14.5% | 2,543 | +0.5% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 2,530 | +3.6% | 0.00% | – |
| Q2 2022 | $1,000 | -93.8% | 2,443 | -65.2% | 0.00% | – |
| Q1 2022 | $16,000 | -84.2% | 7,025 | -67.1% | 0.00% | – |
| Q4 2021 | $101,000 | +461.1% | 21,332 | +864.4% | 0.00% | – |
| Q3 2021 | $18,000 | +12.5% | 2,212 | 0.0% | 0.00% | – |
| Q2 2021 | $16,000 | -83.0% | 2,212 | -81.3% | 0.00% | – |
| Q1 2021 | $94,000 | -68.7% | 11,831 | -68.9% | 0.00% | – |
| Q4 2020 | $300,000 | +29.3% | 38,057 | +16.7% | 0.00% | – |
| Q3 2020 | $232,000 | -25.9% | 32,613 | -3.7% | 0.00% | – |
| Q2 2020 | $313,000 | -1.9% | 33,869 | -50.6% | 0.00% | – |
| Q1 2020 | $319,000 | -24.9% | 68,501 | +22.9% | 0.00% | – |
| Q4 2019 | $425,000 | -0.9% | 55,720 | -0.1% | 0.00% | – |
| Q3 2019 | $429,000 | +2.4% | 55,789 | -8.9% | 0.00% | – |
| Q2 2019 | $419,000 | +28.5% | 61,235 | +51.3% | 0.00% | – |
| Q1 2019 | $326,000 | +11.3% | 40,463 | +3.6% | 0.00% | – |
| Q4 2018 | $293,000 | +64.6% | 39,067 | +110.0% | 0.00% | – |
| Q3 2018 | $178,000 | -67.8% | 18,600 | -64.4% | 0.00% | – |
| Q2 2018 | $552,000 | +103.7% | 52,199 | +91.4% | 0.00% | – |
| Q1 2018 | $271,000 | +118.5% | 27,272 | +19.0% | 0.00% | – |
| Q4 2017 | $124,000 | +36.3% | 22,921 | +23.7% | 0.00% | – |
| Q3 2017 | $91,000 | +7.1% | 18,530 | -16.4% | 0.00% | – |
| Q2 2017 | $85,000 | -27.4% | 22,153 | +41.1% | 0.00% | – |
| Q1 2017 | $117,000 | +56.0% | 15,705 | -9.1% | 0.00% | – |
| Q4 2016 | $75,000 | +316.7% | 17,281 | +517.2% | 0.00% | – |
| Q3 2016 | $18,000 | +63.6% | 2,800 | +21.7% | 0.00% | – |
| Q2 2016 | $11,000 | – | 2,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $532,000 | 6.17% |
| Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
| GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
| Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
| Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
| Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
| Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
| Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |